A follow-up genetic investigation using optical genome mapping and karyotyping has identified a balanced paracentric chromosomal inversion disrupting the DMD gene in a 3-year-old boy clinically diagnosed with Duchenne muscular dystrophy after routine diagnostic methods yielded negative results. Researchers reported that while conventional testing protocols successfully diagnose over 90 percent of clinical cases, rare structural rearrangements can evade standard diagnostic workflows. In this clinical evaluation, the optical genome mapping technique successfully fine-mapped the chromosomal rearrangement breakpoints, revealing a gene disruption in intron 41 that provided a definitive molecular genetic diagnosis for the young patient.
Duchenne muscular dystrophy is an X-linked recessive disorder that primarily affects males, characterized by progressive skeletal and cardiac muscle degeneration caused by the absence of functional dystrophin protein in muscular tissue. According to clinical background evidence, approximately one-third of individuals with the condition also experience intellectual disability. Pathogenic variants responsible for the condition typically involve copy number variants, including multi-exonic deletions found in roughly 60 to 70 percent of cases and duplications in 5 to 15 percent of cases. Single nucleotide variants and small insertion-deletions account for about 20 percent of cases, whereas deep intronic variants causing splicing defects and complex structural variants such as inversions and translocations occur very rarely, representing roughly 1 to 2 percent of the overall pathogenic variant spectrum.
Standard diagnostic investigations for suspected Duchenne muscular dystrophy rely primarily on next-generation sequencing and multiplex ligation-dependent probe amplification analysis. Together, these routine tests identify pathogenic variants in more than 90 percent of clinically diagnosed patients. However, a small subset of patients remain without a confirmed molecular genetic diagnosis following standard diagnostic panels, predominantly due to complex structural variants or deep intronic changes that lie beyond the detection limits of conventional assays. For patients who test negative on initial screens, additional testing modalities capable of resolving cryptic structural alterations are essential to confirm the diagnosis and circumvent invasive procedures.
The patient described in the case report was evaluated by pediatric neurologists at age 3 due to developmental delay. Medical records indicated that he had achieved independent walking at 2 years of age and exhibited a hypotonic habitus. Laboratory testing revealed a markedly elevated serum creatine kinase level of 25,478 U/l. These laboratory findings, in combination with motor delay, physical clumsiness, a positive Gowers sign, and mild calf hypertrophy, prompted a strong clinical suspicion of Duchenne muscular dystrophy. In addition to physical symptoms, clinical specialists documented developmental delays in cognitive skills, language acquisition, and social interaction.
Family history and clinical assessments indicated that the patient was the first-born child of the family. His mother exhibited an elevated creatine kinase level of 2,135 U/l and reported experiencing some muscle stiffness in her legs along with a personal history of learning difficulties during school. Further familial investigation showed that the proband’s maternal uncle was unaffected, and no other members of the family had been diagnosed with any neuromuscular disease, suggesting an isolated presentation within the household.
Initial genetic investigations focused on detecting exonic copy number variants in the DMD gene using multiplex ligation-dependent probe amplification analysis. When this initial testing returned negative, clinicians conducted an extensive series of routine diagnostic investigations. These secondary assays included targeted next-generation sequencing of the DMD gene, fragile-X testing, single nucleotide polymorphism-based comparative genomic hybridization array testing, and trio-exome sequencing encompassing both the index patient and his parents. All of these extensive routine genetic evaluations yielded completely negative results, leaving the underlying cause unsolved.
To investigate potential cytogenetic abnormalities, clinicians performed chromosome G-banding analysis, which revealed a seemingly balanced paracentric inversion on the short arm of the X chromosome, designated with estimated cytoband breakpoints at p22.31 and p21.2. Because the estimated proximal breakpoint resided in the same cytogenetic band as the 3-prime end of DMD at p21.2, chromosome disruption was suspected but could not be definitively confirmed by light microscopy. Fluorescence in situ hybridization analysis using whole chromosome X painting probes and X and Y chromosome p-arm telomere region probes subsequently confirmed the paracentric inversion while definitively ruling out translocations involving other chromosomes.
To achieve high-resolution mapping of the structural rearrangement, researchers applied optical genome mapping to the patient’s sample. This analysis refined the structural variant to inv(X)(p22.2p21.1) and established its overall size at approximately 18.9 megabase pairs. High-resolution mapping situated the proximal breakpoint within intron 41 of the DMD gene between coordinates chrX:32,330,404 and 32,337,248 under genome build GRCh38. The distal breakpoint mapped to an intergenic region at p22.2 between coordinates chrX:13,447,650 and 13,483,855, with tilde designations reflecting the method’s positional uncertainty.
Identification of the proximal breakpoint within intron 41 directly confirmed the physical disruption of the DMD gene, establishing a definitive molecular genetic diagnosis for the index patient. Establishing this molecular diagnosis facilitated targeted carrier testing across the maternal pedigree. G-banding and optical genome mapping confirmed that the patient’s mother carried the identical inversion. Further diagnostic evaluation demonstrated that the maternal grandmother was a non-carrier, indicating that the inversion most likely arose as a de novo mutation in the mother, which provides critical information for clinical genetic counseling and calculating recurrence risks.
A review of medical literature identified several studies published over the past decade in which balanced DMD inversions were detected using long-read sequencing technologies and optical genome mapping in patients with negative routine tests. All previously documented pathogenic inversions preventing production of the full-length primary muscle dystrophin isoform Dp427m varied in breakpoint locations and sizes. One previously reported patient shared an intron 41 breakpoint with the current case; however, that earlier individual did not present with neurodevelopmental deficits, illustrating phenotypic divergence despite similar intragenic breakpoints.
Researchers suggested that the genomic context into which DMD exons 42 through 79 were translocated might influence phenotypic expression, particularly regarding neurodevelopment. In the current patient, exons 42 through 79 were relocated into a transcriptionally silent intergenic region at Xp22.2, which may impair the transcription of specific shorter dystrophin isoforms such as Dp140 that are implicated in cognitive functioning and brain development. Both rearrangement breakpoints may therefore play important roles in dictating cognitive phenotypes in patients with balanced chromosomal rearrangements.
The study highlights specific technical boundaries and advantages associated with optical genome mapping in clinical genomics. Although the technology does not provide single-nucleotide breakpoint resolution and cannot detect structural variants smaller than 500 base pairs, its resolution is sufficient to characterize large structural variants in monogenic disorders. For mutation-negative Duchenne cases, optical genome mapping offers a non-invasive diagnostic alternative that can confirm clinical diagnoses and circumvent invasive muscle biopsies that are otherwise required to assess the absence of dystrophin protein.
The comprehensive genetic evaluation extended beyond the immediate family unit to assess transmission patterns and recurrence risks across the broader pedigree. Because chromosomal structural variants can occasionally originate from parental germline mosaicism, clinical geneticists recommended carrier testing utilizing both karyotyping and optical genome mapping for the proband’s maternal aunt, an asymptomatic adult whose testing results remained pending at the time of publication. In contrast, the patient’s maternal grandfather and maternal uncle were asymptomatic adults who did not undergo carrier testing. Beyond confirming the index patient’s diagnosis, establishing the exact molecular lesion provides actionable clarity for reproductive genetic counseling, enabling the family to pursue targeted prenatal diagnosis or preimplantation genetic testing during future pregnancies to prevent recurrence.
To place these findings in a broader investigative framework, the authors conducted a targeted literature search using defined proximity parameters, specifically querying the terms “DMD inversion” within twenty-five words across titles and abstracts in PubMed and throughout full-text articles in PubMed Central. This search identified several studies published over the past decade in which balanced inversions disrupting DMD were resolved through long-read technologies, including optical genome mapping and long-read sequencing, following inconclusive standard testing. These accumulated reports demonstrate that although standard molecular assays successfully diagnose more than ninety percent of individuals with Duchenne muscular dystrophy, cryptic balanced rearrangements constitute a persistent, clinically consequential cause of disease in patients who remain genetically unsolved after routine screening panels.
The investigators highlighted the mechanistic factors that make balanced chromosomal inversions particularly challenging for standard short-read sequencing workflows to capture. Inversions are frequently mediated by repetitive genomic sequences that flank rearrangement junctions, creating ambiguous alignments and assembly gaps that prevent short-read bioinformatics pipelines from identifying the structural alteration. In contrast, optical genome mapping images continuous high-molecular-weight DNA molecules, ensuring that the analytical process is not confounded by repetitive sequence elements. Because of its monogenic nature and the known causal role of complex structural variants, mutation-negative Duchenne muscular dystrophy represents an exceptionally well-suited clinical scenario where targeted optical genome mapping can successfully deliver decisive gene-level insights.
The study authors also emphasized that evaluating both rearrangement breakpoints provides crucial biological insight into the phenotypic variation seen among affected individuals. While gene disruption at the intragenic breakpoint directly halts dystrophin production, the location of the reciprocal distal breakpoint determines the surrounding genomic environment into which displaced exons are placed. In cases involving balanced chromosomal rearrangements, characterizing both distal and proximal breakpoint contexts may illuminate why certain patients experience cognitive impairment while others do not, warranting broader adoption of long-read optical platforms to explore unexplained phenotypic differences in complex cytogenetic cases.
Subject of Research: Optical genome mapping of a cryptic balanced inversion disrupting the DMD gene in Duchenne muscular dystrophy
Article Title: Optical genome mapping identifies a balanced inversion disrupting DMD in a patient with Duchenne muscular dystrophy
Article References: Turtinen, T., Isohanni, P., Anttonen, A.-K., Huhti, L., Pylkäs, K., Tikkanen, M., Hakonen, A. H., Strang-Karlsson, S., & Mantere, T. (2025). Optical genome mapping identifies a balanced inversion disrupting DMD in a patient with Duchenne muscular dystrophy. Molecular Cytogenetics, 19(1), Article 4. https://doi.org/10.1186/s13039-025-00743-2
Image Credits: AI Generated
DOI: 10.1186/s13039-025-00743-2
Keywords: Duchenne muscular dystrophy, optical genome mapping, DMD gene, chromosomal inversion, structural variants, intron 41, karyotyping, multiplex ligation-dependent probe amplification, creatine kinase, dystrophin, pediatric neurology, genetic counseling, X-linked inheritance, fluorescence in situ hybridization, whole exome sequencing, paracentric inversion, G-banding analysis
News Source: Juliet Wilcox. (November 21, 2026). Optical Genome Mapping Resolves Cryptic DMD Gene Inversion in Duchenne Case. Scienmag.



